Corneal Collagen as a Potential Therapeutic Target in Dry Eye Disease. R.O. Baratta, E. Schlumpf, B.J. DelBuono, S. De Lorey, and D.J. Calkins. (2021) Survey of Ophthalmology May/June.
– – – – – – – – –
Collagen Mimetic Peptides Promote Corneal Epithelial Cell Regeneration. R.O. Baratta, B. J. Del Buono, E. Schlumpf, B.Ceresa, and D.J. Calkins. Frontiers in Pharmacology 2021 (12) 1-8.
– – – – – – – – –
Efraim Y, Chen FYT, Stashko C, Cheong KN, Gaylord E, McNamara N, Knox SM. Alterations in corneal biomechanics underlie early stages of autoimmune-mediated dry eye disease. J Autoimmun. 2020 Nov;114:102500. doi: 10.1016/j.jaut.2020.102500. Epub 2020 Jun 18. PMID: 32565048; PMCID: PMC8269964.
Stuart’s ST-100, which has demonstrated corneal nerve repair and neuroprotection capabilities in pre-clinical studies, achieved a variety of endpoints in its dry eye disease Phase 2 trial, consistent with a first of its kind nerve reparative approach to the disease, and also addressing all of the DEWS II consequences.
Epithelial cells of multiple types produce and interact with the extracellular matrix to maintain structural integrity and promote healthy function within diverse endogenous tissues. Collagen is a critical component of the matrix, and challenges to collagen’s stability in aging, disease,and injury influence survival of adherent epithelial cells…
Vision loss through the degeneration of retinal ganglion cell (RGC) axons occurs in both chronic and acute conditions that target the optic nerve.
Optic neuropathies are a major cause of visual disabilities worldwide, causing irreversible vision loss through the degeneration of retinal ganglion cell (RGC) axons, which comprise…
Eric Schlumpf, President & CEO of Stuart Therapeutics, has extensive experience leading early-stage companies in various industries.
Eric Schlumpf, president and CEO of Stuart Therapeutics, took a winding path to launch his South Florida-based eye-care company. Along the way, he met academic researchers…
The cornea of the eye is at risk for injury through constant exposure to the extraocular environment. A highly collagenous structure, the cornea contains several different types distributed across multiple layers. The anterior-most layer contains…
Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol technology and associated patents through license. At Stuart Therapeutics, we are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications. We are interested in strategic partner relationships that will extend and accelerate our impact.